Another interesting and highly relevant phenomenon in AMI patients undergoing PCI—specifically diabetic patients with AMI—is the impact of SGLT2-inhibitors on acute kidney injury (AKI) caused by contrast. Here, SLC5A2 is linked to acute kidney injury.